A Mab A Case Study In Bioprocess Development | SIMPLE ✮ |

| Metric | Target | Achieved | Result | |--------|--------|----------|--------| | Overall yield | >70% | 73% | Success | | Final titer | 5 g/L | 5.2 g/L | Success | | Aggregates | <1% | 0.6% | Success | | HCP | <100 ppm | 18 ppm | Success | | Potency (relative to reference) | 80-125% | 105% | Success | | Cost of goods (COGs) per gram | <$100 | $78 | Target beat | | Timeline (clone to Phase I) | 18 months | 16 months | Ahead of plan |

The is a landmark document in the biopharmaceutical industry, serving as a comprehensive blueprint for applying Quality by Design (QbD) principles to monoclonal antibody (mAb) development . Published in 2009 by the CMC Biotech Working Group , it remains a primary educational resource for understanding how to integrate regulatory guidelines (ICH Q8, Q9, and Q10) into real-world manufacturing. Key Takeaways & Core Concepts

This content is suitable for a bioprocess engineering blog, a technical whitepaper, or an educational slide deck.